BRCA1 and ovarian carcinoma: As an example, the combination of methotrexate (targets folate synthesis) and erlotinib (EGFR inhibitor) in UWB1289 (BRCA1-mutant ovarian carcinoma) cells is antagonistically efficacious and potent by MuSyC, but synergistic by Loewe (Fig. 3C).